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Background. The World Health Organization is planning a pilot introduction of a new malaria vaccine in three sub-
Saharan African countries. To inform considerations about including a new vaccine in the vaccination program of
those and other countries, estimates from the scientific literature of the incremental costs of doing so are important.
Methods. A systematic review of scientific studies reporting the costs of recent vaccine programs in sub-Saharan
countries was performed. The focus was to obtain from each study an estimate of the cost per dose of vaccine admi-
nistered excluding the acquisition cost of the vaccine and wastage. Studies published between 2000 and 2018 and
indexed on PubMed could be included and results were standardized to 2015 US dollars (US$). Results. After succes-
sive screening of 2119 titles, and 941 abstracts, 58 studies with 80 data points (combinations of country, vaccine type,
and vaccination approach–routine v. campaign) were retained. Most studies used the so-called ingredients approach
as costing method combining field data collection with documented unit prices per cost item. The categorization of
cost items and the extent of detailed reporting varied widely. Across the studies, the mean and median cost per dose
administered was US$1.68 and US$0.88 with an interquartile range of US$0.54 to US$2.31. Routine vaccination
was more costly than campaigns, with mean cost per dose of US$1.99 and US$0.88, respectively. Conclusion. Across
the studies, there was huge variation in the cost per dose delivered, between and within countries, even in studies
using consistent data collection tools and analysis methods, and including many health facilities. For planning pur-
poses, the interquartile range of US$0.54 to US$2.31 may be a sufficiently precise estimate.
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Introduction
When contemplating introduction of a new health care
intervention for the first time, an accurate estimation of
its full costs based on real-world data will usually not be
available. Whereas it is increasingly recognized that
rational decision making on the allocation of health care
resources requires comprehensive assessments of the out-
comes and benefits as well as the costs of interventions,
it may be necessary to base decisions on provisional,
approximate data.1,2 One approach to resolve this
dilemma is to examine the costs of interventions that are
similar to the one under consideration and which have
already been implemented in the jurisdiction of interest
or elsewhere.1,2
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A case in point is the newly developed RTS,S vaccine
candidate against malaria, which is considered for intro-
duction in several African sub-Saharan countries, where
the disease burden of malaria is still heavy. Despite sus-
tained progress in the fight against malaria with an esti-
mated decrease in malaria deaths worldwide of 60% since
2000, estimations from the World Health Organization
(WHO) indicate that around 438,000 individuals died of
malaria in 2015.3 More than 90% of these deaths occurred
in sub-Saharan Africa and most of them were children
under the age of 5 years.
The RTS,S vaccine candidate received a positive eva-
luation by the European regulatory authorities and
WHO is planning to conduct a pilot implementation of
the vaccine in three sub-Saharan countries with moderate
to high malaria transmission intensity.3 To inform the
consideration about including the RTS,S vaccine candi-
date as part of the Expanded Program on Immunization
of these countries, estimates of the anticipated incremen-
tal costs of doing so are highly relevant and important.4
The purpose of this study was to have a clear overview
of the methods and estimates for vaccine implementation
costs from the scientific literature. This review supports
the design and allows comparison with results obtained
from a field study conducted in five African sub-Saharan
countries (Burkina Faso, Ghana, Kenya, Mozambique,
and Tanzania) to derive an estimate of the anticipated
costs of introducing the RTS,S vaccine candidate in sub-
Saharan countries. This field study is described in the
accompanying paper.5 This review of the literature
focuses on studies reporting the costs of recent vaccine
programs in these countries. Ideally, such studies should
be using micro-costing principles with itemized costs and
separate reporting of quantities of resources and their
unit prices. However, relatively few studies based on
these principles have been published until now, although
the importance of using this approach is increasingly
recognized and guidelines for their performance, report-
ing, and appraisal are under preparation.6,7 We grant
that the scarcity of studies in this area may be somewhat
a function of our limited search (we used only one data-
base). We therefore applied less strict criteria for inclu-
sion of studies, but at minimum, studies should report
itemized costs or a cost per dose delivered to be selected.
Further inclusion criteria are detailed in the next section.
Methods
Systematic Search Strategy
PubMed was searched for relevant articles published
between 2000 and the end of 2018 using the following
search string:
(((((((vaccine OR vaccination) OR immunization)
AND (economic OR cost)) AND (‘‘2000/1/1’’[Date -
Publication]: ‘‘2018/12/31’’[Date - Publication]))))) AND
(Africa OR country x). The countries specified were
Benin, Burkina Faso, Burundi, Cameroon, Central
African Republic, Chad, The Democratic Republic of
Congo, Côte d’Ivoire/Ivory Coast, Djibouti, Eritrea,
Ethiopia, Gambia, Ghana, Guinea, Guinea Bissau,
Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali,
Mauritania, Mozambique, Niger, Rwanda, Senegal,
Sierra Leone, Somalia, Sudan, Tanzania, Togo, Uganda,
Zambia, and Zimbabwe.
Screening
First, the title of the identified articles was screened, then
the abstract of the retained possibly relevant articles, and
finally the full text of papers retained after the two
screening steps. The reference lists of the retained articles
for full text screening were also examined and possibly
relevant ones included in the screening steps. Papers were
excluded if they specifically focused on non-GAVI
(Global Alliance for Vaccines and Immunization) or
non-African countries, if they were about nonhuman
vaccines, and if they were written in languages other than
English and French.
The criteria for selection of articles were: 1) costing
study performed in a GAVI-supported sub-Saharan
African country (or more than one) in order to have a
more homogeneous set of countries in terms of income
level and health system status; 2) study performed
between 2000 and 2018; 3) costing performed for a
human vaccine; 4) costs itemized and quantified; item-
ized costs reported in monetary terms or as percentages
of an overall cost figure reported in monetary terms; and
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5) possibility to calculate a comprehensive cost per dose
administered, excluding the costs of vaccine.
Data Extraction
The data extracted from each selected study include the
authors’ report of the costs of vaccination per dose. If
the cost per dose was presented in the article, this figure
was used as such. If the reported cost figure included the
cost of the vaccine, we subtracted the vaccine cost from
this or the proportion of non-vaccine costs in the total
costs was applied. If a study reported the cost per fully
vaccinated child (FVC), this figure was divided by the
number of doses required for a FVC and, if necessary,
the cost of the vaccine was deducted as well. For studies
reporting detailed, itemized costs, the cost per dose was
calculated as the sum of the itemized costs excluding the
costs of vaccine and wastage. We did not have an a priori
definition for wastage, and took wastage as the value
defined by the study authors. In one particular case, the
study reported a cost figure calculated as the weighted
average of administration in urban and rural facilities
based on the number of facilities of the respective type.8
For this study, we recalculated the cost per dose using
the weighted average of the number of doses adminis-
tered in urban versus rural facilities.
Categorization
For cost items, the following categories were used and
their proportion of the total cost per dose calculated to
the extent possible: human resources, transportation,
administration, equipment, sensitization, training, and
surveillance. Explicit definitions for each category were
not created; instead, we ‘‘agnostically’’ relied on the defi-
nitions used by authors themselves, and used common
sense for classifying those expenditures that did not use
the same jargon as our categories (e.g., ‘‘awareness’’ was
classified as ‘‘sensitization,’’‘‘salaries’’ were classified as
‘‘human resources,’’ etc.). These categories were used to
follow an approach similar to the one developed for the
field study as described in the accompanying paper.
Perspective and Challenges
We only took into account the cost from the program/
providers’ perspective. Though this excludes a great deal
of the true economic cost of vaccine programs, this lim-
ited perspective is most relevant to the aim of this study,
and most applicable to estimating potential program
costs for the rollout of an intervention.
If incremental or marginal costs were mentioned in a
study, that figure was preferably used rather than an
average economic cost per dose in order to account for
the actual budgetary requirement for the introduction of
a new vaccine in the program. Though incremental costs
are more variable and are highly contingent on local
capacity, this approach was in line with our study’s aim
than looking at full economic program costs. However,
distinctions between cost types such as fixed and vari-
able, start-up, and recurrent were not retained, because
they were used inconsistently across studies, sometimes
overlapping, sometimes insufficiently categorized, and
sometimes in incompatible ways.
Some studies do not specify the vaccine purchase cost
separately but combine it with injection material and
other supplies. In such cases, we decided to eliminate the
entire cost item including both vaccine and injection
material costs, given that the costs of injection supplies
generally are small compared with the vaccine purchase
cost. Some studies do not explicitly mention the vaccine
price,9–13 but they may mention the source of data; in
such cases, we retrieved it from the data source, mostly
the UNICEF website.14
In other situations, it was not possible to remove the
cost of wastage because it was not separately reported in
the study and was therefore a nonobserved component
of the final cost. If a study reported wastage separately,
this item was not included in our calculation of the cost
per dose.
Wastage is a major cost that is included in most stud-
ies but not always based on field data and often included
in the vaccine cost and not reported separately. Wastage
costs may be very high according to some studies12,15 and
there are several difficulties involved in handling them.
Wastage costs depend mainly on the vaccine price and
the level of the health care system at which the wastage
occurs, with variation between routine vaccinations in
health facilities and outreach activities or vaccination
campaigns. Wastage also varies with the number of doses
per vial, the service volume in terms of number of vacci-
nations administered, and the vaccine characteristics. As
a consequence, the costs related to wastage vary widely
and may be difficult to capture fully. For these reasons
we did not include wastage as a separate cost category in
the cost estimation.
Monetary Homogenization
All the studies report costs in US dollars (US$) for a
base year, usually the year the cost data were collected.
All the cost figures were converted to 2015 US$ using
Brew and Sauboin 3
data from the World Bank.16 This conversion was per-
formed in 3 steps: 1) conversion from US$ to the local
currency unit (LCU) for the base year reported in the
study; 2) taking inflation into account by applying the
consumer price index increase in the LCU from the
base year until and including 2015; and 3) converting
the inflation corrected figure back to 2015 US$. The
search query was devised by CS. The initial search was
carried out by JB; iterative screening was carried out
by both JB and CS.
Results
Screening Results
The process of articles selection is summarized in Figure
1 with details on the reasons for exclusion. The initial
search returned 2119 articles. Based on the title alone,
941 were retained and 1178 were eliminated for one of
the following reasons (from the most to least common
reason): 1) no or insufficient economic content, 2) not
vaccination of humans, 3) not about a vaccine, 4) not
about an African GAVI country, 5) article withdrawn,
or 6) not in English or French.
The abstract of the 941 retained articles were read,
and based on this, 778 articles were excluded for one of
the following reasons (from the most to least common
reason): 1) no cost researched, retrieved, reported or not
in relation with vaccine administration; 2) cost not
related to vaccine delivery or was for delivery in a spe-
cific emergency context; 3) no abstract found or not in
English/French or article withdrawn; 4) not vaccination
in humans; 5) not in African GAVI country; 6) vaccina-
tion of special subgroups not including children; 7) opin-
ion paper, review, qualitative study, meeting report; or
8) not about a vaccine.
The remaining 163 articles were screened based on the
full text and 108 were excluded based on one of the fol-
lowing reasons (from the most to least common reason):
1) referring to another article (added or already included
in the articles reviewed), 2) no delivery cost or no doses
reported, 3) limited to specific cost items (often injection
or logistics), 4) based on assumptions or models only, 5)
special vaccination context (e.g., refugees, outbreak,
emergency), 6) referring to another article that could not
be found/included, 7) not in African country, 8) the vac-
cine price could not be segregated from the cost, or 9)
data not available or accessible in journal supplement.
In addition to the 55 articles selected by this procedure,
three more were included after examination of eight arti-
cles found in the reference lists of selected articles. The
other five were excluded because they focused on special
emergency situations (2), only logistics costs (1), or did
not allow elimination of the vaccine purchase cost (1).
The 58 articles contained 80 data points, that is, combi-
nations of country, vaccine type, and vaccination approach
(routine or campaign). The 22 countries included had a
preponderance of East African countries, and the most
Papers identified by search string in PubMed: 2,119
Papers excluded: 1,178
Reasons for exclusion:
No economic content: 477
Not in humans: 313
Not about vaccine: 203






No cost data or not related to vaccine delivery: 644
Cost not related to vaccine delivery or related to 
special emergency: 83
No abstract found, not in English/French, paper 
withdrawn: 17
Not vaccination in humans: 10
Not African GAVI country: 10
Vaccination of groups not including children: 8
Opinion paper, review, etc.: 6
Full text papers screened: 163
Papers excluded: 108
Reasons for exclusion:
Referring to another paper already included: 35
No delivery cost or no doses reported: 30
Limited to specific type of cost: 20
Based on assumptions only: 7
Special context (e.g., refugees, emergency): 6
Referring to paper or supplement not found: 4
Not in African country: 2
Unable to remove vaccine price: 4
Papers included in review: 55
Relevant papers from reference lists: 3 selected out of 8 
examined
All papers included in review: 58
Figure 1 Selection of articles.
GAVI, Global Alliance for Vaccines and Immunization.
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frequently represented were Tanzania (9/80), Uganda (9),
Zambia (8), Ethiopia (7), Ghana (6), Kenya (4), and
Burkina Faso (4). One study aggregated data for 27
African countries,17 and another one aggregated data on
HPV immunization for 10 African countries.18
Altogether 11 different vaccines including a category
defined as ‘‘multiple vaccines’’ when vaccines could not
be distinguished were examined, and those costed in the
58 data points on routine vaccination were multiple vac-
cines (17), measles (8), malaria (8), rotavirus (7), human
papillomavirus (HPV; 8), hepatitis B virus (HBV; 5),
pneumococcal conjugate vaccine (PCV; 4), and meningi-
tis (1). The vaccines included in the 22 data points for
campaign-type vaccination were predominantly measles
(8), cholera (7), and meningitis (3), with the remaining
including typhoid, yellow fever, and multiple vaccines.
Most studies used the so-called ingredients approach
as costing method, combining field data collection with
documented unit prices for each cost item. One clear
example of this is the EPIC (Extended Program of
Immunization Costing and Financing) project, which
collected data for routine vaccination cost using the same
consistent methods in around 50 vaccine delivery facili-
ties in each of four African GAVI countries (and two
non-African).8,19,20 Of the 80 data points, 55 (69%) are
based on primary cost data collected in field studies, with
some variation in the extent of field data collection and
in some cases limited to interviews with health workers.
For a minority of studies,17,20–25 the costing is based
on existing budget plans (such as comprehensive multi-
year plans (cMYP) or financial plans for immunization
of the Ministry of Health). An average cost of adminis-
tration is then calculated based on the total cost and the
number of doses planned. One study in Nigeria26 is based
on the cost of administration estimated in a study in
Tanzania,27 with an adaptation limited to the difference
in purchasing power.
Several studies of vaccination campaigns are based on
all the costs incurred over a relatively short time period
in the campaign and recorded in financial accounts or
reports on the campaign.28–33
A number of studies are actually mainly cost-
effectiveness analyses just reporting the cost of vaccina-
tion used as an input, sometimes based on primary col-
lection of field data.9,21,24,25,34–41 The initial PubMed
search returned several more cost-effectiveness studies
but these were excluded because they based their cost
estimates on cost data from papers included in the
review. The cost-effectiveness analyses retained in the
review have either collected primary cost data or are
based on other studies.
Analysis
The studies are summarized in Table 1 with a brief indi-
cation of the methods used by the authors for the cost
estimation and the estimated average cost per dose in
2015 US$. All the costs extracted are estimated from the
perspective of the public health authorities.
The aggregate cost results are summarized in Table 2,
with overall average and median cost per dose of US$1.68
and US$0.88, respectively, and a range from US$0.16 to
US$13.58. For routine vaccinations, the average and
median cost per dose are US$1.99 and US$1.17, respec-
tively, and for campaign-type vaccinations US$0.88 and
US$0.66, respectively. The histogram in Figure 2 shows
the distribution of cost results in intervals of US$0.25.
For both types of vaccination approach, the major part
of the average cost results is in the interval US$0.25 to
US$1.50, with 33/58 of the routine vaccination studies
and 20/22 of the campaign-type studies.
The cost per dose varies with the type of vaccine as
shown in Table 3. HPV is an outlier with average and
median costs of US$5.20 and US$3.84, respectively, for
routine vaccinations, far above the corresponding cost
figures for other routine vaccination programs. These
aggregates are very much determined by a single study in
Mali with a cost of US$13.58,42 but even disregarding
that study the costs are high, with a range of average
costs for the remaining five HPV studies from US$1.1843
to US$5.21.26 A multi-country study found an average
cost of US$8.30 per dose administered.18 The reason for
the elevated costs may be that HPV vaccines are typically
delivered through a bundling with school-based or out-
reach programs, which require more training and per-
sonnel. If HPV vaccinations are excluded from the
aggregation, the average cost for routine programs
would be US$1.47 instead of US$1.99.
There was a tendency for the newer studies to be more
comprehensive including further cost categories such as
the costs of social mobilization/sensitization and surveil-
lance programs. The results regarding the proportion of
the total cost per dose accounted for by each cost cate-
gory are based on the studies for which these data were
available. Sixteen of the 58 articles do not report any
data on cost categories,9,22,23,25,28,35,37,38,40,41,44–49 and
one study only provides details on transportation, repre-
senting 17% of the total cost per dose.50 Table 4 presents
the number of data points for each cost category and its
average proportion of the cost per dose based on the
available data (Note: the average proportions are not
supposed to sum to 100 across the cost categories due to
the gaps in the reporting of categories). Human resources
and transportation are the most frequently reported
ðtext continues on p: 12Þ






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































categories and surveillance the least. The average propor-
tions vary somewhat between the vaccination approaches,
in particular, for human resources, administration, and
equipment. Overall, human resources account for almost
half (44%) of the average cost per dose followed by
administration, transportation, and building/equipment
(each about 20%).
Discussion
This review and summary analysis of vaccination costing
studies performed in sub-Saharan African countries
shows that the estimated cost per dose (excluding vaccine
and wastage costs) varies substantially across studies.
Even though the costing methods used are fairly consis-
tent, predominantly using an ingredients approach with
Table 2 Summary of Cost per Dose Delivered
Average Median Lower Quartile Upper Quartile
Overall 1.68 0.88 0.54 2.31
Routine 1.99 1.17 0.59 2.66
Campaign 0.88 0.66 0.40 1.13
Figure 2 Number of data points reporting average cost in cost intervals of US$ 0.25.













Yellow fever 0.41 0.41
HBV, hepatitis B vaccine; HPV, human papilloma virus; PCV,
pneumococcal conjugate vaccine.
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data collection by questionnaires, interviews, or reports,
the studies lack standardization with respect to which
cost items are reported and how these are reported, so
their findings are not easily comparable. We suspect that
a large part of the variation in the estimated costs reflects
differences in what is reported under each cost category.
It should be noted, however, that the largest study in
our review using consistent methods and tools of data
collection and cost estimation for approximately 50
health facilities in each of four sub-Saharan African
countries also finds high variability between (and within)
the countries with a more than threefold difference
between the minimal and maximal cost per dose, that is,
US$0.77 in Benin and US$2.67 in Ghana. The study
authors consider that the estimated variation reflects real
differences between the countries in unit prices, charac-
teristics of the health systems, and in the practical orga-
nization of the vaccination programs.20 Of note, the per
capita income in Ghana is more than double that in
Benin, the countries in that study with the highest and
lowest cost per dose, respectively, so the unit costs of
labor and other resources are much higher in Ghana.51
Across the studies, personnel costs amounted to
approximately half the cost per dose. Labor time is a
shared resource, which requires estimation of both the
proportion of the time of each type of personnel to vacci-
nation activities and within vaccination the allocation of
time to different activities. Allocation of labor time is
probably one of the cost categories most difficult to esti-
mate reliably without direct observation, because respon-
dents may be motivated to report a particular allocation
of effort. Interestingly, the above-mentioned four-
country study reports a substantial reduction of the
labor cost per dose with an increasing vaccination activ-
ity (number of doses administered per time period),
which suggests improving efficiency through economies
of scale in the use of labor with rising vaccination
activity.20 However, such a possible relationship has not
been investigated in other studies in this review.
Our findings are similar to results reported by Portnoy
et al.,52 which estimate the cost of vaccination programs
in 94 low- and middle-income countries using model-
based costs and cMYP planned budgets. The reported
average cost per dose for routine and campaign delivery
approaches in low income countries is (2010)US$1.75
when the vaccine cost is excluded, similar to our average
of (2015)US$1.68 across the GAVI countries. Human
resources cost categories are also identified as the most
important but with a higher proportion (82%) than in
our study, although this figure includes both low- and
middle-income countries. Another recent review reports
a range of the incremental economic cost for newly intro-
duced vaccines (PCV and rotavirus vaccines) between
(2016)US$0.48 to US$1.38 in Benin, Rwanda, and
Uganda. These results are also close to our findings with
means of (2015)US$0.81 and US$1.57 for these two
vaccines.53
Among the specific difficulties encountered in allocat-
ing costs into one of the categories we had predefined,
were that some papers disclosed more details than the
specified categories, for instance, reporting the cost of
personnel time devoted to training; in such cases we had
to choose the higher level category in which to allocate
the cost. The reverse problem also occurred, where
papers reported aggregated categories (e.g., transporta-
tion and equipment combined). In such cases we allo-
cated the cost to the category expected to represent the
highest cost. Another type of situation was that a cate-
gory used in a study did not match the ones we selected.
An example would be ‘‘cold chain,’’ which could either
be part of the equipment (fridges) in a health facility or
related to transportation of vaccines. In such cases we
qualitatively based the cost allocation on elements of the
text description in the paper.
Table 4 Mean Proportion of Cost per Dose for Each Cost Category from the Studies Reporting Each Item
Category
Number of Data Points (Total = 56) Average Share of the Cost Without Vaccine and Wastage
a
Total Routine Campaign Total Routine Campaign
Human resources 55 43 12 44% 47% 37%
Transportation 51 40 11 20% 20% 22%
Administration 45 34 11 20% 17% 27%
Equipment 38 30 8 18% 20% 12%
Sensitization 38 29 9 10% 10% 11%
Training 33 25 8 7% 8% 3%
Surveillance 11 9 2 5% 5% 5%
aThe total exceeds 100% because the average share is calculated across studies which include the cost category.
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We found that routine vaccination programs generally
have higher reported costs than introduction campaigns
even though some campaigns have very high human
resources costs. The likely reasons for the lower cost of
vaccination campaigns is that they require less capital
investment in health facilities than routine vaccination,
and/or capital investments are not considered into these
studies. A further hypothesis is that this finding might be
explained by a tendency for costing studies of routine vac-
cination programs to be thorough and comprehensive,
whereas costing of campaigns or introduction programs
perhaps tend to focus most on those costs that differed
from routine programs. This somewhat counterintuitive
finding could also be explained by the fact that studies did
not generally report or describe differences in financial ver-
sus economic costs. Accordingly, we were unable to per-
form separate financial versus economic analyses. This,
unfortunately, limits the generalizability of our study.
Authors more frequently reported incremental costs
instead of average economic costs. Though this is helpful in
determining the marginal cost of a hypothetical program to
be rolled out, this also poses an important limitation to the
applicability of our study: since incremental costs is highly
contingent on local capacity and infrastructure, its variabil-
ity is high, and its generalizability is low. Additionally, item-
ized summary statistics should be interpreted with caution,
since our inclusion criteria was fairly broad, and because of
the incompatibility of cross-study categorizations.
We included several studies with ‘‘multiple’’ vaccines
because they were integration campaigns (i.e., integrating a
new vaccine into an existent multi-vaccine program, or
rolling out an intervention with multiple vaccines). This
may lead to some cost inflation that would not have
occurred were we to have limited our study pool to only
those programs which administered one vaccine in isola-
tion. However, we chose not to adopt such a restriction
because 1) it would have reduced our sample significantly,
ignoring otherwise useful information from multiple pro-
grams, and 2) it would have imposed a condition on costs
which hypothetically might not even correspond to the
rollout of an RTS,S campaign in the future (i.e., there is
no reason to suggest at this point that RTS,S would not be
rolled out in the framework of an ‘‘integrated’’ program).
Although some studies make a clear distinction between
the cost of existing programs and the cost of introducing a
new vaccine, most studies do not systematically separate
capital costs and recurrent costs or average versus incre-
mental costs. Very few studies make it clear how discount-
ing of capital costs (including training costs as investments
in human capital with an expected depreciation period of
some years) has been handled. Capital cost is in general
annualized based on the life expectancy of equipment but
with limited information.
The studies generally apply a provider or health care
system perspective and few studies consider the wider
societal perspective by, for example, taking into account
the costs for families in terms of transport and opportu-
nity costs such as time lost for other activities when
accompanying their child for vaccination. However, the
wider societal perspective is mostly relevant for a com-
prehensive evaluation of the economic value of vaccina-
tion and less relevant if the purpose of the assessment is
more specifically to understand the cost structure to pos-
sibly improve efficiency and reduce costs.
Our aim was to support the design of a field study to
estimate the cost of RTS,S rollout. Also by generalizing
to vaccines as a whole, our results may be generalizable
to vaccine campaigns at large, rather than just RTS,S.
A limitation of this review is that we used one data-
base (PubMed) for our search, which may have limited
the numbers of studies identified. There may be addi-
tional studies published in peer-reviewed journals, and it
is likely there are numerous small specific studies in the
gray literature that have been overlooked. Nevertheless,
this review of 58 articles provides an indication of the
likely cost estimates and potential budget required for
introducing a new vaccine. To conclude, given the wide
variation in the cost per dose (between and within coun-
tries) even in studies using consistent data collection tools
and analysis methods across a large number of health
care facilities in several countries, it would not be reason-
able to try to fix a point estimate for the costs per dose.
When considering inclusion of a new vaccine in countries
targeted by this review, perhaps the overall interquartile
range of US$0.54 to US$2.31 estimated here could serve
as a reasonably precise baseline estimate but at the coun-
try level it would be useful to perform cost estimations
strictly following the guidelines already available.
It would thus be commendable in future studies to
adopt the method of the EPIC studies with a distinction
between resource items (such as personnel, equipment,
vehicles, buildings, etc.) and the various functions or
activities each of these are used for. For example, person-
nel are participating in training, so the cost item is ‘‘per-
sonnel cost’’ but the actual activity is indeed ‘‘training.’’
In this review, we have observed that studies use incon-
sistent approaches with regard to reporting costs by item
or by activity, making aggregation and comparison diffi-
cult. Combining cost items and activities in a matrix for
cost calculation as proposed by Brenzel et al.54 and illu-
strated in Figure 3 could greatly increase transparency
and improve the understanding of the cost structure and









































































































































































































































































































































































































































































































































































its determinants in order to increase efficiency and help
planning resource requirements and financing needs.
Additionally, aggregate studies such as this one would be
of greater accuracy and applicability were the component
costs categorized more consistently and transparently.
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